U.S. Markets closed

BioVie Inc. (BIVI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
15.70+0.18 (+1.16%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.52
Open15.73
Bid15.13 x 900
Ask17.00 x 1000
Day's Range15.13 - 15.95
52 Week Range7.50 - 46.10
Volume20,500
Avg. Volume62,958
Market Cap350.633M
Beta (5Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-7.33
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.00
  • BioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
    GlobeNewswire

    BioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference

    Trial will be first Phase 3 disease modifying anti-inflammatory insulin sensitizer therapy in Alzheimer’s diseaseSANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that Poster 55458 entitled “Rationale for an Anti-inflammatory Insulin Sensitizer in a Phase 3 Alzheimer’s Disease Trial” by Christopher L Reading, PhD, BioV

  • Basis for BioVie’s Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer’s Disease Published in Neurodegenerative Disease Management
    GlobeNewswire

    Basis for BioVie’s Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer’s Disease Published in Neurodegenerative Disease Management

    Pivotal Phase 3 Trial of NE3107 Expected to Commence in Summer 2021SANTA MONICA, Calif., July 16, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that an article summarizing the scientific rationale for the Company’s upcoming pivotal Phase 3 Trial of its NE3107 asset in Alzheimer’s disease has been published in the medical journal Neurodegenerativ

  • Development of BioVie’s NE3107 Asset Featured by the American Diabetes Association
    GlobeNewswire

    Development of BioVie’s NE3107 Asset Featured by the American Diabetes Association

    NE3107 Featured in the ADA’s Thought Leadership Film Series at Annual Scientific SessionSANTA MONICA, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, announced today that a video documentary detailing the development history of the Company’s newly acquired NE3107 asset will be featured in the American Diabetes Association's